Comparison
Both Epitalon and Pinealon are short bioregulator peptides developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, and both are associated with pineal gland biology and aging research. Epitalon is a tetrapeptide with an established research profile centred on telomerase activation and broad longevity outcomes; Pinealon is an EDR tripeptide with a more focused profile on neural tissue gene expression and circadian or cognitive targets. Their mechanisms and research profiles are complementary rather than redundant.
| Attribute | Epitalon | Pinealon |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG tetrapeptide) | Glu-Asp-Arg (EDR tripeptide) |
| Developer | Khavinson et al., Institute of Bioregulation and Gerontology, St. Petersburg | Khavinson et al., Institute of Bioregulation and Gerontology, St. Petersburg |
| Primary mechanism | Telomerase activation (TERT expression upregulation); epigenetic chromatin remodelling; melatonin regulation | Neural tissue gene expression modulation; neuroprotective chromatin binding; pineal and circadian pathway involvement |
| Primary research focus | Longevity, telomere biology, anti-aging, melatonin/circadian, immune support | Neuroprotection, circadian regulation, cognitive support, pineal biology |
| Routes | SubQ injection; oral (investigational, lower bioavailability) | SubQ injection; oral (investigational) |
| Commonly reported doses | 5–10 mg/day SubQ for 10–20 day courses, 1–2× per year | 100–200 mcg/day SubQ, typically shorter courses |
| Research maturity | More extensive; multiple animal longevity studies, human observational data, telomerase mechanism well-characterised | Earlier stage; primary data from Khavinson group publications; mechanism being characterised |
The most significant difference is the breadth and focus of their respective research profiles. Epitalon has been investigated across a wider range of aging-related outcomes: telomere elongation and telomerase activation, melatonin secretion restoration in aging animals, immune function support, anti-tumour effects in animal models, and lifespan extension in rodent studies. Pinealon's research profile is more focused, concentrating on neural tissue gene expression, neuroprotection, and the circadian system, particularly in contexts of hypoxia, aging, or neurodegeneration.
At the molecular level, both peptides are proposed to act through chromatin-level gene regulation: the short bioregulator peptides developed by the Khavinson group are thought to interact with histone proteins and DNA to modulate gene expression in a tissue-selective manner. Epitalon's chromatin binding is proposed to be broader, particularly in epithelial and immune cells, while Pinealon's activity is proposed to be more selective for neural tissue. This selectivity, if confirmed, would explain their different research profiles from a common mechanistic basis.
Dosing conventions also differ. Epitalon is most commonly reported in courses of 5–10 mg/day for 10–20 days, repeated one to two times per year. Pinealon research protocols are less standardised, with lower commonly reported doses and shorter or more flexible course lengths. Both reflect the broader Khavinson bioregulator peptide approach of periodic short courses rather than continuous administration.
Epitalon (Ala-Glu-Asp-Gly) was originally isolated from pineal gland extract. Its best-characterised mechanism is the induction of telomerase reverse transcriptase (TERT) expression, which activates the telomerase enzyme responsible for elongating or maintaining telomere length. In aging organisms, telomerase activity declines and telomeres shorten progressively with each cell division, contributing to cellular senescence. Research has investigated Epitalon for its potential role in restoring or upregulating telomerase activity. Additional reported mechanisms include restoration of melatonin synthesis (which declines with age partly due to reduced pineal gland function), normalisation of circadian rhythms, and anti-oxidant activity.
Pinealon (Glu-Asp-Arg) is a more recently characterised member of the Khavinson bioregulator peptide family. Research has investigated its potential role in modulating gene expression in neural tissues through chromatin-binding interactions, protecting neurons from hypoxic and oxidative stress, and influencing circadian clock gene expression. Its proposed neural tissue selectivity (based on in vitro data showing preferential uptake or activity in neuronal cell lines compared to other tissues) distinguishes it from Epitalon's broader tissue profile.
Epitalon research has investigated its potential role in:
Pinealon research has investigated its potential role in:
Both Epitalon and Pinealon are reported to have minimal side effects in the available research and anecdotal literature. Reported side effects in research and anecdotal accounts for both primarily include injection site reactions (mild redness, swelling) and occasional temporary fatigue or mild sedation. Epitalon's more extensive research base has not surfaced consistent serious adverse event patterns. Pinealon's research base is smaller, and its tolerability profile is less comprehensively characterised.
Yes, and this is one of the more commonly described combinations in the Khavinson bioregulator peptide research community. Epitalon's broader longevity and telomere-focused activity and Pinealon's neural-tissue-selective neuroprotective and circadian activity address different biological targets. Combining them in a protocol that uses Epitalon for systemic aging biomarker support and Pinealon for neural and circadian-specific effects represents a logical research approach given the complementary mechanisms. No formal co-administration protocol exists in the published literature; anecdotal accounts vary in the timing relationship between the two course-based compounds.
Research contexts focused on telomere biology, cellular aging, longevity biomarkers, and melatonin/circadian restoration in the context of systemic aging research are better matched to Epitalon, given its more extensive and directly relevant research literature. Epitalon is also the more commonly used compound in anti-aging peptide protocols, providing a larger anecdotal reference base.
Research contexts focused on neural tissue specifically, neuroprotection, circadian disruption in the context of neurological aging, or cognitive support are better matched to Pinealon, given its proposed neural selectivity and research focus in those domains. Where both neural and systemic aging targets are relevant to the research question, the two compounds are described in the literature as a natural pairing.
Bioregulator peptides (also called cytomedins or peptide bioregulators) are short peptides (typically 2–5 amino acids) first described by the Khavinson group in the 1970s. They are proposed to act as endogenous gene-regulatory signals that modulate tissue-specific gene expression through chromatin interaction. The theory holds that different tissue types have characteristic short peptide sequences with regulatory roles in gene expression, and that supplementing these peptides externally can restore or support tissue function, particularly in aging or disease states.
Animal studies, primarily in rodents and some invertebrate models, have reported lifespan extension with Epitalon treatment, with published studies from the Khavinson group reporting 12–30% increases in mean and maximum lifespan. Human data is limited to observational and case series level; no randomised controlled trial with lifespan as an endpoint has been published in humans, and the mechanistic extrapolation from rodent telomere biology to human longevity outcomes is not fully established.
Pinealon's proposed tissue selectivity is for neural tissue, based on in vitro uptake and gene expression data suggesting preferential activity in neuronal cell lines. However, systemic administration means it circulates throughout the body. Whether its in vivo activity is truly neural-selective or whether it has broader systemic effects at research doses is not fully characterised in the available literature. Most published research has investigated neural endpoints specifically.
Epitalon was originally derived from pineal gland extract research and is thought to support pineal gland function. Research has documented that aging animals treated with Epitalon show partially restored melatonin secretion patterns that had been blunted with age. Melatonin is primarily produced by the pineal gland and is a key circadian regulator; its age-related decline is thought to contribute to sleep disruption and circadian dysfunction in older individuals. Epitalon is not melatonin and does not bind the melatonin receptor; rather, it is proposed to support the gland's own melatonin-producing capacity.